Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NYSE:QGEN NASDAQ:ROIV NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$19.76-1.1%$20.68$19.15▼$26.58$2.44B0.851.45 million shs1.67 million shsQGENQiagen$45.39+0.2%$48.42$37.63▼$51.88$10.07B0.641.32 million shs1.01 million shsROIVRoivant Sciences$13.95-0.9%$11.93$8.73▼$14.48$9.61B1.156.44 million shs6.72 million shsRVMDRevolution Medicines$46.20-0.8%$38.13$29.17▼$62.40$8.70B1.121.99 million shs1.70 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-1.05%-1.59%-2.32%-14.90%-2.27%QGENQiagen+0.20%-4.67%-8.04%-2.56%+0.71%ROIVRoivant Sciences-0.92%+8.06%+17.72%+25.56%+16.83%RVMDRevolution Medicines-0.75%+12.52%+27.20%+18.04%+5.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$19.76-1.1%$20.68$19.15▼$26.58$2.44B0.851.45 million shs1.67 million shsQGENQiagen$45.39+0.2%$48.42$37.63▼$51.88$10.07B0.641.32 million shs1.01 million shsROIVRoivant Sciences$13.95-0.9%$11.93$8.73▼$14.48$9.61B1.156.44 million shs6.72 million shsRVMDRevolution Medicines$46.20-0.8%$38.13$29.17▼$62.40$8.70B1.121.99 million shs1.70 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-1.05%-1.59%-2.32%-14.90%-2.27%QGENQiagen+0.20%-4.67%-8.04%-2.56%+0.71%ROIVRoivant Sciences-0.92%+8.06%+17.72%+25.56%+16.83%RVMDRevolution Medicines-0.75%+12.52%+27.20%+18.04%+5.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$33.2068.02% UpsideQGENQiagen 2.27Hold$49.699.47% UpsideROIVRoivant Sciences 3.50Strong Buy$17.6726.64% UpsideRVMDRevolution Medicines 3.07Buy$73.6759.45% UpsideCurrent Analyst Ratings BreakdownLatest CPRX, QGEN, RVMD, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025RVMDRevolution MedicinesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $73.009/12/2025RVMDRevolution MedicinesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$72.009/11/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$67.00 ➝ $70.009/11/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$73.00 ➝ $77.009/11/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $66.009/5/2025RVMDRevolution MedicinesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$99.009/2/2025ROIVRoivant SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight ➝ Buy$16.008/19/2025CPRXCatalyst PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025RVMDRevolution MedicinesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$75.008/18/2025RVMDRevolution MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/15/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$67.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M4.92$2.42 per share8.16$6.10 per share3.24QGENQiagen$2.04B4.95$3.21 per share14.13$16.05 per share2.83ROIVRoivant Sciences$29.05M327.92N/AN/A$7.45 per share1.87RVMDRevolution MedicinesN/AN/AN/AN/A$13.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.6511.989.280.8037.36%40.78%35.36%11/5/2025 (Estimated)QGENQiagen$83.59M$1.6926.8218.452.3918.30%14.77%8.87%11/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)Latest CPRX, QGEN, RVMD, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/5/2025Q2 2025QGENQiagen$0.60$0.60N/A$0.44$523.97 million$533.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AQGENQiagen$0.250.55%N/A14.79%N/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.716.55QGENQiagen0.251.611.35ROIVRoivant SciencesN/A40.5440.54RVMDRevolution Medicines0.1311.7911.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%QGENQiagen70.00%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%QGENQiagen9.00%ROIVRoivant Sciences10.80%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.39 million109.66 millionOptionableQGENQiagen5,765222.29 million202.29 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableCPRX, QGEN, RVMD, and ROIV HeadlinesRecent News About These CompaniesInsider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 25,000 Shares of Stock3 hours ago | insidertrades.comQ3 EPS Estimates for Revolution Medicines Reduced by WedbushSeptember 16 at 2:08 AM | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 6,877 Shares of Revolution Medicines, Inc. $RVMDSeptember 15 at 3:30 AM | marketbeat.comIntech Investment Management LLC Has $3.81 Million Holdings in Revolution Medicines, Inc. $RVMDSeptember 15 at 3:19 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, The Goldman Sachs Group Analyst SaysSeptember 15 at 2:43 AM | americanbankingnews.comWedbush Predicts Reduced Earnings for Revolution MedicinesSeptember 15 at 2:09 AM | americanbankingnews.comThe Goldman Sachs Group Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) StockSeptember 14 at 1:33 PM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Given "Strong-Buy" Rating at Raymond James FinancialSeptember 14 at 8:26 AM | marketbeat.comWedbush Research Analysts Lower Earnings Estimates for RVMDSeptember 14 at 7:09 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Up Following Analyst UpgradeSeptember 13 at 10:14 AM | marketbeat.comWells Fargo & Company Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock PriceSeptember 13 at 8:51 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $77.00September 13 at 8:51 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Given New $66.00 Price Target at Needham & Company LLCSeptember 13 at 8:16 AM | marketbeat.comDynamic Technology Lab Private Ltd Invests $502,000 in Revolution Medicines, Inc. $RVMDSeptember 13 at 3:58 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Coverage Initiated by Analysts at Raymond James FinancialSeptember 13 at 3:45 AM | americanbankingnews.comSiren L.L.C. Sells 7,793 Shares of Revolution Medicines, Inc. $RVMDSeptember 13 at 3:12 AM | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) StockSeptember 13 at 2:55 AM | americanbankingnews.comNeedham & Company LLC Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) StockSeptember 13 at 2:55 AM | americanbankingnews.comWedbush Issues Pessimistic Estimate for RVMD EarningsSeptember 13 at 2:58 AM | americanbankingnews.comFred Alger Management LLC Has $4.15 Million Position in Revolution Medicines, Inc. $RVMDSeptember 12, 2025 | marketbeat.comRevolution Medicines (RVMD) Announces Promising Phase 1 Daraxonrasib Clinical Trial ResultsSeptember 12, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPRX, QGEN, RVMD, and ROIV Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$19.76 -0.21 (-1.05%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$19.84 +0.08 (+0.40%) As of 07:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Qiagen NYSE:QGEN$45.39 +0.11 (+0.24%) Closing price 09/15/2025 03:59 PM EasternExtended Trading$45.53 +0.14 (+0.31%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Roivant Sciences NASDAQ:ROIV$13.95 -0.13 (-0.92%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$13.76 -0.19 (-1.35%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$46.20 -0.35 (-0.75%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$46.40 +0.20 (+0.42%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
